Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T16:28:24.767Z.
Calculation as of: 2026-10-06T16:28:24.767Z.
Quote observation: 2026-10-06T16:25:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 954f90b5803147d7e77bb33cb230df589f2ac0b2215919e8afc4fbf9605c1a4a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$238.23M
EV/FCF Ratio
N/A
TTM Avg
3.75x
3Y Avg
11.33x
5Y Avg
12.44x
Market Cap
$221.87M
EV/FCF Ratio
N/A
TTM Avg
0.76x
3Y Avg
0.76x
5Y Avg
0.76x
Market Cap
$239.42M
EV/FCF Ratio
3.43x
TTM Avg
5.14x
3Y Avg
5.14x
5Y Avg
5.14x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $228.93M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $230.08M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $233.59M | N/A | 75.46x | 75.46x | 75.46x |
| BioAge Labs Inc. (BIOA)vs › | $232.72M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $236.81M | 25.39x | 23.33x | 20.20x | 22.09x |
| SIGA Technologies, Inc. (SIGA)vs › | $238.23M | N/A | 3.75x | 11.33x | 12.44x |
| Keros Therapeutics, Inc. (KROS)vs › | $221.87M | N/A | 0.76x | 0.76x | 0.76x |
| InflaRx N.V. (IFRX)vs › | $238.61M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $239.42M | 3.43x | 5.14x | 5.14x | 5.14x |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $239.92M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
